Abstract
BackgroundDiagnosis of multiple endocrine neoplasia type 1 (MEN1) is commonly based on clinical criteria, and confirmed by genetic testing. In patients without known MEN1-related germline mutations, the possibility of a casual association between two or more endocrine tumors cannot be excluded and subsequent management may be difficult to plan. We describe a very uncommon case of functioning glucagonoma associated with primary hyperparathyroidism (pHPT) in which genetic testing failed to detect germline mutations of MEN-1 and other known genes responsible for MEN1.Case presentationThe patient, a 65-year old woman, had been suffering for more than 1 year from weakness, progressive weight loss, angular cheilitis, glossitis and, more recently, skin rashes on the perineum, perioral skin and groin folds. After multidisciplinary investigations, functioning glucagonoma and asymptomatic pHPT were diagnosed and, since family history was negative, sporadic MEN1 was suspected. However, genetic testing revealed neither MEN-1 nor other gene mutations responsible for rarer cases of MEN1 (CDKN1B/p27 and other cyclin-dependent kinase inhibitor genes CDKN1A/p15, CDKN2C/p18, CDKN2B/p21). The patient underwent distal splenopancreatectomy and at the 4-month follow-up she showed complete remission of symptoms. Six months later, a thyroid nodule, suspected to be a malignant neoplasia, and two hyperfunctioning parathyroid glands were detected respectively by ultrasound with fine needle aspiration cytology and 99mTc-sestamibi scan with SPECT acquisition. Total thyroidectomy was performed, whereas selective parathyroidectomy was preferred to a more extensive procedure because the diagnosis of MEN1 was not supported by genetic analysis and intraoperative intact parathyroid hormone had revealed “adenoma-like” kinetics after the second parathyroid resection. Thirty-nine and 25 months after respectively the first and the second operation, the patient is well and shows no signs or symptoms of recurrence.ConclusionsDespite well-defined diagnostic criteria and guidelines, diagnosis of MEN1 can still be challenging. When diagnosis is doubtful, appropriate management may be difficult to establish.
Highlights
Diagnosis of multiple endocrine neoplasia type 1 (MEN1) is commonly based on clinical criteria, and confirmed by genetic testing
Multiple endocrine neoplasia type 1 (MEN1) is a rare inherited autosomal dominant syndrome characterized by variable combinations of primary hyperparathyroidism, pancreatic endocrine tumors (PETs) (40-70% penetrance), and anterior pituitary tumors (30-40% penetrance) [1]
Other germline mutations involving four cyclindependent kinase inhibitor genes (CDKN1A/p15, CDKN2C/ p18, CDKN2B/p21 and CDKN1B/p27) and, in patients with pituitary tumors, the Aryl hydrocarbon receptor Interacting Protein (AIP) gene have been found in a minority of patients with clear MEN1 phenotype [3,4,5]
Summary
The case presented here illustrates the fact that diagnosing MEN1 can remain difficult despite the giant strides made in diagnostic imaging and genetic research. Where, as in this case, strict adherence to the current guidelines is not feasible, appropriate management may be difficult to establish. NA, SL and MP participated in the study design and helped to draft the manuscript. AN participated in the study design and in critical revision of the manuscript. Author details 1General Surgery Unit, Department of Surgical Sciences, San Giovanni di Dio Hospital, University of Cagliari, Cagliari, Italy.
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have